| Searching for peripheral biomarkers in neurodegenerative diseases: the tryptophan-kynurenine metabolic pathway N Török, M Tanaka, L Vécsei International journal of molecular sciences 21 (24), 9338, 2020 | 116 | 2020 |
| Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians R Török, N Török, L Szalardy, I Plangar, Z Szolnoki, F Somogyvari, ... Neuroscience Letters 551, 70-74, 2013 | 75 | 2013 |
| Co-players in chronic pain: neuroinflammation and the tryptophan-kynurenine metabolic pathway M Tanaka, N Török, F Tóth, Á Szabó, L Vécsei Biomedicines 9 (8), 897, 2021 | 67 | 2021 |
| Crosstalk between existential phenomenological psychotherapy and neurological sciences in mood and anxiety disorders L Balogh, M Tanaka, N Török, L Vécsei, S Taguchi Biomedicines 9 (4), 340, 2021 | 59 | 2021 |
| Memantine and kynurenic acid: current neuropharmacological aspects Z Majláth, N Török, J Toldi, L Vécsei Current Neuropharmacology 14 (2), 200-209, 2016 | 54 | 2016 |
| Are 5-HT1 receptor agonists effective anti-migraine drugs? M Tanaka, N Török, L Vécsei Expert Opinion on Pharmacotherapy 22 (10), 1221-1225, 2021 | 47 | 2021 |
| Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase Influenced the Age Onset of Parkinson’s Disease N Török, R Maszlag-Török, K Molnár, Z Szolnoki, F Somogyvári, K Boda, ... | 40* | |
| Novel pharmaceutical approaches in dementia M Tanaka, N Török, L Vécsei NeuroPsychopharmacotherapy, 1-18, 2020 | 31 | 2020 |
| High‐throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis K Tripolszki, D Török, D Goudenège, K Farkas, A Sulák, N Török, ... Brain and Behavior 7 (4), e00669, 2017 | 30 | 2017 |
| Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis K Tripolszki, B Csányi, D Nagy, A Ratti, C Tiloca, V Silani, É Kereszty, ... Neurobiology of aging 53, 195. e1-195. e5, 2017 | 27 | 2017 |
| Investigational α-synuclein aggregation inhibitors: hope for Parkinson’s disease N Török, Z Majláth, L Szalárdy, L Vécsei Expert opinion on investigational drugs 25 (11), 1281-1294, 2016 | 27 | 2016 |
| Brain aging and disorders of the central nervous system: kynurenines and drug metabolism N Toeroek, Z Majlath, F Fueloep, J Toldi, L Vecsei Current drug metabolism 17 (5), 412-429, 2016 | 25 | 2016 |
| The rs13388259 Intergenic Polymorphism in the Genomic Context of the BCYRN1 Gene Is Associated with Parkinson’s Disease in the Hungarian Population S Márki, A Göblös, E Szlávicz, N Török, P Balicza, B Bereznai, A Takáts, ... Parkinson’s Disease 2018 (1), 9351598, 2018 | 23 | 2018 |
| An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson’s disease R Török, D Zádori, N Török, É Csility, L Vécsei, P Klivényi Neuroscience letters 610, 135-138, 2016 | 21 | 2016 |
| Investigation of vitamin D receptor polymorphisms in amyotrophic lateral sclerosis N Török, R Török, P Klivényi, J Engelhardt, L Vécsei Acta Neurologica Scandinavica 133 (4), 302-308, 2016 | 14 | 2016 |
| The genetic link between Parkinson’s disease and the kynurenine pathway is still missing N Török, R Török, Z Szolnoki, F Somogyvári, P Klivényi, L Vécsei Parkinson’s Disease 2015 (1), 474135, 2015 | 14 | 2015 |
| NeuroPsychopharmacotherapy M Tanaka, N Török, L Vécsei | 12 | 2021 |
| Novel pharmaceutical approaches in dementia M Tanaka, N Török, L Vécsei NeuroPsychopharmacotherapy, 2803-2820, 2022 | 11 | 2022 |
| Co-Players in Chronic Pain: Neuroinflammation and the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines 2021, 9, 897 M Tanaka, N Török, F Tóth, Á Szabó, L Vécsei | 8 | |
| Promising therapeutic agents for the treatment of Parkinson’s disease Z Majláth, N Török, J Toldi, L Vécsei Expert Opinion on Biological Therapy 16 (6), 787-799, 2016 | 7 | 2016 |
